Skip to content

You can have confidence in your biosimilar medicines

Learn more
Switching to biosimilars is safe and effective for patients
Learn more

Who we are

Biosimilars Canada is a national association representing the biosimilar medicines industry in Canada. We provide leadership in educating Canadian stakeholders about the safety and efficacy of biosimilar medicines, and advocate for policies that support their timely approval, reimbursement, market acceptance and expanded use.

About Biosimilars

As patents for original brand biologic medicines expire other manufacturers can produce new versions called biosimilars. Health Canada authorizes biosimilars for sale using the same rigorous regulatory standards as for all other biologic drugs, and there are no clinically meaningful differences in efficacy and safety between a biosimilar and the original brand biologic medicine.


Learn more about biosimilars and their benefits for patients and healthcare systems.

Latest news

Biosimilars Canada Announces Re-Election of Board Chair and Vice-Chair

Toronto – May 7, 2024 – Biosimilars Canada is pleased to announce the unanimous re-election of Mr. Mike Woolcock, Senior Vice President of Biosimilars and Specialty Products with Apotex, as Chair of the Biosimilars Canada Board. Mr. Mike Casia, President...
Read more

CGPA and Biosimilars Canada Statement on Proposed Pharmacare Legislation

The generic and biosimilar medicines industries will need to learn more about the Government of Canada’s approach to implementation, and consult with key stakeholders, to help ensure that a transition to this program would maximize the use of cost-saving generic and biosimilar medicines, while protecting Canada’s drug supply and domestic manufacturing capacity.
Read more

New Canadian biosimilars resource

Health Canada has published a Handbook for health care professionals on biosimilar biologic drugs. 

Read more